Literature DB >> 16412214

CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.

Werner Kempf1.   

Abstract

CD30+ lymphoproliferative disorders of the skin (CD30+ LPD) represent a well-defined spectrum of primary cutaneous T-cell lymphomas which have been recognized as distinct entities in recent lymphoma classifications. Lymphomatoid papulosis and anaplastic large-cell lymphoma share the expression of CD30 antigen as a common phenotypic hallmark but differ in regard to their clinical and histologic features as well as their biologic behavior. This article summarizes the histologic features of CD30+ LPD and presents recently identified new clinicopathologic variants of CD30+ LPD. There is an increasing number of reactive inflammatory disorders and neoplastic diseases which are composed of or contain a significant number of CD30+ cells and mimic LyP or anaplastic large cell lymphoma clinically or histologically. Differential diagnostic considerations focus on other lymphoproliferative processes with CD30+ tumor cells as well as non-lymphoid neoplasms and inflammatory simulators. The term CD30+ pseudolymphoma is proposed to designate inflammatory processes with CD30+ T cells. The final diagnosis of CD30+ LPD is based on a synthesis of clinical, histologic, phenotypic, and molecular genetic findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412214     DOI: 10.1111/j.0303-6987.2006.00548.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  A case of primary cutaneous anaplastic large cell lymphoma with prominent epidermotropism.

Authors:  Tomomitsu Miyagaki; Makoto Sugaya; Akie Miyamoto; Kunihiko Tamaki; Satoshi Ota; Shinichi Sato
Journal:  Int J Hematol       Date:  2012-03-27       Impact factor: 2.490

2.  Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity.

Authors:  Melissa G Lechner; Stephen Lade; Daniel J Liebertz; H Miles Prince; Garry S Brody; Howard R Webster; Alan L Epstein
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  Primary cutaneous anaplastic large cell lymphoma in a young child.

Authors:  Te-Yu Hung; Yu-Cheng Lin; Hai-Lun Sun; Min-Chang Liu
Journal:  Eur J Pediatr       Date:  2007-01-12       Impact factor: 3.183

4.  Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task.

Authors:  Michael D Diamantidis; Athanasios Papadopoulos; Georgia Kaiafa; George Ntaios; Georgia Karayannopoulou; Ioannis Kostopoulos; Fotios Girtovitis; Zoi Saouli; Zisis Kontoninas; Ioannis D Raptis; Christos Savopoulos; Apostolos Hatzitolios
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490

Review 5.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

6.  Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Authors:  Jing Chen; Yong Zhang; Michael N Petrus; Wenming Xiao; Alina Nicolae; Mark Raffeld; Stefania Pittaluga; Richard N Bamford; Masao Nakagawa; Sunny Tianyi Ouyang; Alan L Epstein; Marshall E Kadin; Annarose Del Mistro; Richard Woessner; Elaine S Jaffe; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-29       Impact factor: 11.205

7.  Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

Authors:  Eva Geissinger; Petra Sadler; Sabine Roth; Tina Grieb; Bernhard Puppe; Nora Müller; Peter Reimer; Claudia S Vetter-Kauczok; Jörg Wenzel; Irina Bonzheim; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Andreas Rosenwald
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

8.  [Clinical course and therapy of lymphomatoid papulosis. Experience with 17 cases and literature review].

Authors:  D Korpusik; T Ruzicka
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

9.  A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.

Authors:  Hongbo Wang; Wei Wei; Jing-Ping Zhang; Zhihui Song; Yangyang Li; Wenming Xiao; Yijun Liu; Mu-Sheng Zeng; Michael N Petrus; Craig J Thomas; Marshall E Kadin; Masao Nakagawa; Thomas A Waldmann; Yibin Yang
Journal:  Leukemia       Date:  2020-11-12       Impact factor: 12.883

Review 10.  Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?

Authors:  Yann Vincent Charli-Joseph; Michelle Gatica-Torres; Laura Beth Pincus
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.